Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8)
暂无分享,去创建一个
J. Stock | J. Minnerly | R. Barve | M. Tortorella | A. Malfait | J. Turk | C. Storer | D. Weiss | J. Stejskal | M. Zack | K. Shevlin | M. A. Melton
[1] M. Weisman,et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.
[2] D. Griggs,et al. Autoactivation of human ADAM8: a novel pre-processing step is required for catalytic activity. , 2009, Bioscience reports.
[3] K. Dabbagh,et al. Pamapimod, a Novel p38 Mitogen-Activated Protein Kinase Inhibitor: Preclinical Analysis of Efficacy and Selectivity , 2008, Journal of Pharmacology and Experimental Therapeutics.
[4] B. Bresnihan,et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008 , 2008, Annals of the Rheumatic Diseases.
[5] D. Edwards,et al. The ADAM metalloproteinases , 2008, Molecular Aspects of Medicine.
[6] M. Feldmann,et al. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics , 2008, Immunological reviews.
[7] A. Boots,et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen‐induced arthritis: a comparison with neutralization of mouse TNFα , 2008, British journal of pharmacology.
[8] Y. Konttinen,et al. Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction , 2008, Annals of the rheumatic diseases.
[9] A. Cope,et al. Immune-mediated pathways in chronic inflammatory arthritis. , 2008, Best practice & research. Clinical rheumatology.
[10] A. Bendele,et al. Exacerbation of Collagen-Induced Arthritis by Oligoclonal, IL-17-Producing γδ T Cells1 , 2007, The Journal of Immunology.
[11] M. Moss,et al. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. , 2007, Analytical biochemistry.
[12] F. Sánchez‐Madrid,et al. Expression and Regulation of the Metalloproteinase ADAM-8 during Human Neutrophil Pathophysiological Activation and Its Catalytic Activity on L-Selectin Shedding1 , 2007, The Journal of Immunology.
[13] A. Koch,et al. Macrophages and their products in rheumatoid arthritis , 2007, Current opinion in rheumatology.
[14] Y. Okada,et al. ADAMs in cancer cell proliferation and progression , 2007, Cancer science.
[15] D. Sheppard,et al. α9β1: A Novel Osteoclast Integrin That Regulates Osteoclast Formation and Function , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] Xinhua Yu,et al. Dissecting the genetic basis of rheumatoid arthritis in mouse models. , 2006, Current pharmaceutical design.
[17] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[18] K. Horiuchi,et al. Metalloprotease‐disintegrin ADAM8: Expression analysis and targeted deletion in mice , 2005, Developmental dynamics : an official publication of the American Association of Anatomists.
[19] G. Kollias,et al. Tumor Necrosis Factor (TNF) Receptor Shedding Controls Thresholds of Innate Immune Activation That Balance Opposing TNF Functions in Infectious and Inflammatory Diseases , 2004, The Journal of experimental medicine.
[20] S. Santavirta,et al. Increased expression of a novel osteoclast-stimulating factor, ADAM8, in interface tissue around loosened hip prostheses. , 2003, The Journal of rheumatology.
[21] H. Jockusch,et al. The Metalloprotease Disintegrin ADAM8 , 2002, The Journal of Biological Chemistry.
[22] P. Slocombe,et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs , 2002, FEBS letters.
[23] G. Roodman,et al. ADAM8: A Novel Osteoclast Stimulating Factor , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] J. Frazier,et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[25] S. Yamamoto,et al. CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. , 1997, Genomics.
[26] L. Joosten,et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. , 1996 .
[27] B. Koller,et al. A new embryonic stem cell line from DBA/1lacJ mice allows genetic modification in a murine model of human inflammation. , 1995, Experimental cell research.
[28] J. Nadel. Biology of Mast Cell Tryptase and Chymase a , 1991, Annals of the New York Academy of Sciences.
[29] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[30] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[31] H. Luthra,et al. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates , 1981, The Journal of experimental medicine.
[32] Z. Guan,et al. Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8 , 2006, Biological chemistry.
[33] D. Seals,et al. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. , 2003, Genes & development.
[34] C. Blobel,et al. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). , 2003, Current topics in developmental biology.
[35] Z. Werb,et al. Shedding light on sheddases: role in growth and development. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.
[36] R. Caccese,et al. Bacterial lipopolysaccharide potentiates type II collagen-induced arthritis in mice , 1992, Mediators of inflammation.
[37] E. Stanley. Murine bone marrow-derived macrophages. , 1990, Methods in molecular biology.
[38] C. Barnstable,et al. Monoclonal antibodies to human cell surface antigens. , 1979, Haematology and blood transfusion.